Skip to main content

Athira Pharma Inc

For the period ended Jun 30, 2024. Filed Aug 1, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 1, 2024

LONA$4.47+1.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

June 30,December 31,
20242023
(unaudited)
Assets
Current assets:
Cash and cash equivalents$73,828$90,584
Restricted cash, current8,373—
Short-term investments17,94156,835
Prepaid expenses and other current assets4,9345,682
Insurance recovery receivable related to legal settlement (Note 7)1,6281,628
Total current assets106,704154,729
Restricted cash, non-current631631
Property and equipment, net2,9303,388
Operating lease right-of-use asset9331,049
Other long-term assets55448
Total assets$111,253$160,245
Liabilities and stockholders' equity
Current liabilities:
Accounts payable$475$129
Accrued liabilities16,03618,343
Accrued legal settlement (Note 7)10,00010,000
Current operating lease liability391368
Total current liabilities26,90228,840
Operating lease liability, less current portion1,0161,217
Total liabilities27,91830,057
Stockholders' equity:
Common stock, $0.0001 par value; 900,000,000 shares authorized at June 30, 2024 and December 31, 2023, respectively; 38,439,375 and 38,172,603 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively44
Additional paid-in capital445,771439,739
Accumulated other comprehensive loss(38)(349)
Accumulated deficit(362,402)(309,206)
Total stockholders' equity83,335130,188
Total liabilities and stockholders' equity$111,253$160,245
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.